本帖最后由 老马 于 2012-1-13 21:20 编辑
' g$ _: k+ [9 Z: ~( k! d, b D$ n2 b# g3 {' }7 E
爱必妥和阿瓦斯丁的比较: ]1 t: t* L& B) r6 n2 k& L+ ?' f
4 R" [( ?8 c3 P5 Lhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/+ i/ { s5 r; s o1 C
4 i, N A5 n4 _. W/ p' E5 }
; L% Z" r6 x, H; e( z" Xhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/4 }7 Q2 @2 D0 S! r' L- K* l
==================================================
& }* E5 E$ _, `Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)& _0 }; _ ]6 K" D* X7 B
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
; j5 T9 I( c5 N. n" MResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.) M4 O, K6 y( P$ J' r( S1 C3 t% y/ x
|